ERBB2 and gastric cancer: While BVAC-B immunotherapy has shown limited clinical efficacy in HER2-positive GC patients, it activates immune cells and induces HER2-specific antibody responses, suggesting potential for enhanced efficacy in future combination therapies (100).The novel OBI-999, an antibody-drug conjugate targeting Globo H antigens, has shown good tolerability and disease stabilization in GC patients (101).